Bridging the gap between innovation and capital
Xontogeny and Perceptive Advisors
Focus on Biotech Therapeutic Companies
Program
Xontogeny is a life sciences venture studio providing seed and pre-seed investment, along with experienced operational oversight and expertise and a strong network of consultants, advisors and service providers. Xontogeny’s team brings decades of deep operational, strategic, and investment experience across treatment modalities and therapeutic areas with a proven track record of success. The firm prioritizes its energy and resources to focus on the careful design of each component of a company’s product development and regulatory plan, from preclinical lead identification through clinical proof-of-concept data. They believe these choices are essential to the success of any program.
Event
LaunchBio, Citrin Cooperman, and Silicon Valley Bank, a Division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with Xontogeny.
As companies scale, Xontogeny offers a pathway to continued institutional support through Perceptive Advisors, a leading healthcare investment firm whose Perceptive Xontogeny Venture (PXV) Fund is purpose-built to back the next stage of growth for companies emerging from the Xontogeny portfolio.
Applications will be selected based on meeting the following criteria:
Geography
Open to investments in North America
Company type
Early-stage biotech companies focused on therapeutics, medtech, medical devices and digital tech.
Modalities of Interest
- Small molecules
- Biologics
- Protein and RNA-based therapeutics
- Gene therapies and Gene editing technologies
- Cell therapies
- Regenerative medicine & tissue engineering
- Microbiome & engineered living therapies
- Radiopharmaceuticals
- Oncolytic viruses
- Drug-device combinations & advanced delivery platforms
- Diagnostics
- AI/ML-Enabled
Preferred Therapeutic areas include:
- Immunology & Inflammation
- Cardiovascular / Cardiometabolic
- CNS
- Pulmonary
- Ophthalmology
- Rare diseases
- Cancer
Stage
Companies seeking funding for Pre-Seed, Seed, Series A and Series B
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Citrin Cooperman and Silicon Valley Bank, a division of First Citizens Bank.